Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...
Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback